Key Dates

Related Announcements

PAR-19-328 - Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that NHLBI has posted a set of responses to Frequently Asked Questions (FAQs) regarding PAR-19-328: Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required). The FAQs are available on the NHLBI website at the following link: https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities/foa-Investigator-Initiated-Single-site-Clinical-Trials-FAQ.

Applicants are strongly encouraged to review the FAQs, which may be updated at any time without additional notice, prior to submitting their application.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Division of Blood Diseases and Resources
Nahed El Kassar, MD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0065
Email: nahed.elkassar@nih.gov

Division of Cardiovascular Sciences
Yves Rosenberg, MD, MPH
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0550
Email: rosenbey@nhlbi.nih.gov

Division of Lung Diseases
Gail Weinmann, MD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0233
Email: weinmang@nhlbi.nih.gov

Peer Review Contact(s)

Keary A. Cope, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0287
Email: copeka@nhlbi.nih.gov

Financial/Grants Management Contact(s)

Tammi L. Simpson
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8051
Email:tammi.simpson@nih.gov